Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup

This article was originally published in Scrip

Executive Summary

Allergan PLC never really left the market for biopharmaceutical mergers and acquisitions after it entered into a $160bn merger agreement with Pfizer Inc., but now that the deal has been called off the company is free to buy assets large and small that fit its "growth pharma" focus.


Related Content

Activist Investors Seek Action At Allergan, But Are They Aligned?
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Allergan's Fishing For Deals, But Don't Expect A Big Catch





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts